CO4960657A1 - PHARMACEUTICAL COMPOSITION - Google Patents

PHARMACEUTICAL COMPOSITION

Info

Publication number
CO4960657A1
CO4960657A1 CO98047010A CO98047010A CO4960657A1 CO 4960657 A1 CO4960657 A1 CO 4960657A1 CO 98047010 A CO98047010 A CO 98047010A CO 98047010 A CO98047010 A CO 98047010A CO 4960657 A1 CO4960657 A1 CO 4960657A1
Authority
CO
Colombia
Prior art keywords
steroid
pharmaceutical composition
aza
solution according
azaandrost
Prior art date
Application number
CO98047010A
Other languages
Spanish (es)
Inventor
Alan Frank Parr
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO4960657A1 publication Critical patent/CO4960657A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Abstract

Una solución, caracterizada porque comprende una cantidadefectiva terapéuticamente de un esteroide aza activo farmacéuticamente, y un éster de ácido graso de glicerol o propinlenglicol.La solución de conformidad con la reivindicación 1, caracterizado porque el esteroide es un esteroide 4- aza o 6-aza.La solución de conformidad con la reivindicación 2, caracterizado porque el esteroide es una carbonil-4-azaandrost-1-en-3-ona 17-beta-substituida o una carbonil-6-azaandrost-4-en-3-ona 17-beta-substituida. 1Una composición farmacéutica, caracterizada porque comprende la solución de conformidad con cualquier reivindicación previa.A solution, characterized in that it comprises a therapeutically effective amount of a pharmaceutically active steroid aza, and a fatty acid ester of glycerol or propinlenglycol. The solution according to claim 1, characterized in that the steroid is a 4- aza or 6-aza steroid The solution according to claim 2, characterized in that the steroid is a carbonyl-4-azaandrost-1-en-3-one 17-beta-substituted or a carbonyl-6-azaandrost-4-en-3-one 17 -beta-substituted. 1A pharmaceutical composition, characterized in that it comprises the solution according to any previous claim.

CO98047010A 1997-08-19 1998-08-18 PHARMACEUTICAL COMPOSITION CO4960657A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9717428.8A GB9717428D0 (en) 1997-08-19 1997-08-19 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
CO4960657A1 true CO4960657A1 (en) 2000-09-25

Family

ID=10817619

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98047010A CO4960657A1 (en) 1997-08-19 1998-08-18 PHARMACEUTICAL COMPOSITION

Country Status (15)

Country Link
EP (1) EP1007010A2 (en)
JP (1) JP2002511101A (en)
KR (1) KR20010014080A (en)
CN (1) CN1263461A (en)
AR (1) AR016629A1 (en)
AU (1) AU9343098A (en)
BR (1) BR9810458A (en)
CA (1) CA2295016A1 (en)
CO (1) CO4960657A1 (en)
GB (1) GB9717428D0 (en)
MA (1) MA26531A1 (en)
PE (1) PE105699A1 (en)
TR (1) TR199903209T2 (en)
WO (1) WO1999008666A2 (en)
ZA (1) ZA987392B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS6633A (en) * 2002-11-22 2004-05-23 Omega Farma Ehf. Compositions of finasteride tablets
ES2445947T3 (en) 2003-08-13 2014-03-06 Biocon Limited Formulations for solid dosage of fatty acid salts in the form of microparticles for therapeutic agents
JP2007517788A (en) * 2004-01-02 2007-07-05 ファルマコン・フォルシュング・ウント・ベラートゥング・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Process for producing 1,2-unsaturated azasteroids
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
WO2010117873A2 (en) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
ES2385240B1 (en) 2010-07-26 2013-09-23 Gp-Pharm, S.A. CAPSULES OF ACTIVE PHARMACEUTICAL PRINCIPLES AND POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF PROSTATE DISEASES.
US8900631B2 (en) 2011-04-28 2014-12-02 Health Science Funding, LLC Dosage form to increase prasterone bioavailability
CN103169712B (en) * 2011-12-20 2017-10-27 重庆华邦制药有限公司 Improve dutasteride's preparation of bioavilability and preparation method thereof
WO2014002015A1 (en) 2012-06-25 2014-01-03 Ranbaxy Laboratories Limited Pharmaceutical composition comprising dutasteride
ES2555485T1 (en) 2014-05-26 2016-01-04 Galenicum Health S.L. Pharmaceutical compositions containing an active agent
KR101679992B1 (en) * 2015-12-31 2016-11-28 주식회사 유유제약 Pharmaceutical composition comprising dutasteride and propylene glycol monolaurate and preparation method of the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
DE3607651A1 (en) * 1986-03-06 1987-09-10 Schering Ag COMBINATION OF AROMATASE INHIBITORS AND TESTOSTERONE-5 (ALPHA) REDUCTASE INHIBITORS
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
US5550134A (en) * 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss

Also Published As

Publication number Publication date
CN1263461A (en) 2000-08-16
PE105699A1 (en) 1999-11-25
BR9810458A (en) 2000-09-05
GB9717428D0 (en) 1997-10-22
ZA987392B (en) 2000-02-17
JP2002511101A (en) 2002-04-09
MA26531A1 (en) 2004-12-20
CA2295016A1 (en) 1999-02-25
WO1999008666A3 (en) 1999-04-15
KR20010014080A (en) 2001-02-26
EP1007010A2 (en) 2000-06-14
WO1999008666A2 (en) 1999-02-25
TR199903209T2 (en) 2000-05-22
AR016629A1 (en) 2001-07-25
AU9343098A (en) 1999-03-08

Similar Documents

Publication Publication Date Title
ES2176684T3 (en) NEW ASSOCIATIONS OF ACTIVE PRINCIPLES CONTAINING CLOPIDOGREL AND AN ANTHROMBOTIC.
ATE262925T1 (en) IMPROVED DRUG ADMINISTRATION TO MUCOUS SURFACES
DE69826644D1 (en) TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING A CHOLINERGIC ACTIVE SUBSTANCE OR A CALCIUM CHANNEL BLOCKER
ES2155931T3 (en) METHOD OF ADMINISTRATION OF AN ACTIVE AGENT OF PROLONGED RELEASE IN BAND.
TR200100931T2 (en) New sustained release oral formulations
HK1024865A1 (en) Pharmaceutical compositions comprising a mixture of autocross-linked hyaluronic acid and nonautocross-linked hyaluronic acid and their use for the treatment of arthropathies
AR002355A1 (en) COMPOSITIONS AND METHODS FOR LOCAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS.
DE69710065T2 (en) Androstene DERIVATIVES
IL120317A0 (en) Otic antibacterial compositions
CO4960657A1 (en) PHARMACEUTICAL COMPOSITION
ATE241363T1 (en) COMBINATION PREPARATIONS CONTAINING UNSATURATED FATTY ACID AND STEROIDS FOR THE TREATMENT OF INFLAMMATION
BR0010194A (en) Pharmaceutical composition in unit form, containing acetylsalicylic acid and clopidogrel hydrogensulfate
ATE226084T1 (en) WOUND HEALING AND TREATMENT OF FIBROSIS
CA2417935A1 (en) Anti-inflammatory medicament
RU95113437A (en) Trans-2-dimethylamino-1-phenyl-3-cyclohexene-trans-1- carboxylic acid ±-ethyl ester as primary orthophosphate and solid pharmaceutical composition having pain-killing activity
BR0014440A (en) Oral controlled release formulations
PT1043974E (en) LIPOSOMES CONTAINING PEPTIDIC BUILDINGS BRANCHED FOR USE AGAINST HUMAN IMMUNODEFICIENCY VIRUS
AR023705A1 (en) TOPICAL COMPOSITION THAT INCLUDES ANTI-INFLAMMATORY GLUCOCORTICOID HYDROCORTISONE AND AN ANCIIRAL AGENT ANALOG OF NUCLEOSIDE ACICLOVIR AND THE USE OF THE SAME
ES2086518T3 (en) PHARMACEUTICAL COMPOUND WITH HEALING ACTION.
RU94025798A (en) Hydrophilic terpenoid balsam
MX9606254A (en) Anti-inflammatory wound healing compositions and methods for preparing and using same.
CO5011086A1 (en) BUDESONIDE ONLY OR IN COMBINATION WITH URSODESOXICOLIC ACID IN THE LIVER DISEASE THERAPY